Remicade earned approximately $1.47 billion globally in the fourth quarter of 2017, compared with $1.62 billion in the same period in 2016. The overall drop in Remicade sales included an 8.5% slide in US sales, a 5.5% increase in sales of US exports, and an 18.7% decline in international sales.
Johnson & Johnson announced in an investor call today that it earned $20.2 billion in sales for the fourth quarter of 2017 (up 11.5% from the fourth quarter of 2016), including a worldwide increase of 5.1% in its immunology pharmaceutical segment. However, sales of the company’s Remicade (innovator infliximab) fell by 9.7% worldwide as the reference product faced competition from biosimilar drugs.
Remicade earned approximately $1.47 billion globally in the fourth quarter of 2017, compared with $1.62 billion in the same period in 2016. The overall drop in Remicade sales included an 8.5% slide in US sales, a 5.5% increase in sales of US exports, and an 18.7% decline in international sales.
In the United States, the reference Remicade faces competition 2 biosimilar infliximab products: Celltrion and Pfizer’s Inflectra, approved by the FDA and launched in the US market in 2016, and Samsung Bioepis and Merck’s Renflexis, approved and launched in 2017. In the European marketplace, Johnson & Johnson’s drug fights for market share with the same products, where Renflexis is marketed under the brand name Flixabi, and where Inflectra is marketed under 2 names: Inflectra and Remsima.
Despite seeing its profits for infliximab erode from biosimilar competition, Johnson & Johnson’s overall immunology business did report growth of 5.1% for the fourth quarter versus the same period in 2016. Johnson & Johnson said that uptake of Stelara (ustekinumab) for the treatment of Crohn disease was a key driver for growth in for immunology division. Sales of Stelara, which is also indicated for use in patients with plaque psoriasis or psoriatic arthritis (PA), were up 23.0% worldwide in the fourth quarter of 2017, reaching approximately $1.1 billion.
Also continuing to perform well were Simponi (golimumab) and Simponi Aria (an intravenous golimumab that offers less frequent dosing than the subcutaneous Simponi), a treatment for rheumatoid arthritis, PA, ankylosing spondylitis, and ulcerative colitis. Together, the 2 Simponi products were up 15.0% in the fourth quarter of 2017 versus the same period in 2016, reaching approximately $490 million.
Also today, the US Circuit Court of Appeals for the Federal Circuit affirmed a previous ruling that a patent covering the active ingredient in Remicade is invalid. The patent challenge was filed against Johnson & Johnson by Pfizer. According to Bloomberg, shares of Johnson & Johnson dropped by 2.9% after the decision, the biggest intraday decline since April 2017.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.